Overview
Procept Biorobotics Q3 revenue grows 43% yr/yr, beating analyst expectations
Adjusted EBITDA for Q3 beats consensus, showing improved operational performance
Company maintains fiscal yr 2025 revenue guidance, issues optimistic 2026 forecast
Outlook
Company maintains 2025 revenue guidance at $325.5 mln, up 45% from 2024
Company projects 2026 revenue between $410 mln and $430 mln, up 26%-32% from 2025
Company expects $2 mln gross margin headwind in Q4 2025 due to tariffs
Result Drivers
SYSTEM SALES - Increased U.S. system sales to new hospital customers drove revenue growth
CONSUMABLES REVENUE - U.S. handpiece and consumables revenue rose 50% yr/yr, contributing significantly to total revenue
GROSS MARGIN IMPROVEMENT - Improved operational efficiencies led to gross margin expansion to 65%
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $83.32 mln | $80.94 mln (12 Analysts) |
Q3 Net Income | -$21.41 mln | ||
Q3 Adjusted EBITDA | Beat | -$7.39 mln | -$10.19 mln (7 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Procept Biorobotics Corp is $62.00, about 44.3% above its November 3 closing price of $34.51
Press Release: ID:nGNX2fKkfp
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)